Celgene Corp (CELG) 139.01 $CELG
Celgene Rolling Along (but You Already Knew That)
Brian Orelli, The Motley Fool - Motley Fool - Thu Jul 23, 1:47PM CDT
The big picture numbers when Celgene released second quarter earnings Thursday weren't surprising since the company pre-released its revenue and earnings when it announced the acquisition of Receptos last week. But the details of where the...
RCPT: 228.27 (-0.13), ABBV: 70.52 (-0.04), CELG: 139.01 (+0.75)
Celgene (CELG) Earnings Report: Q2 2015 Conference Call Transcript
at The Street - Thu Jul 23, 1:11PM CDT
The following Celgene (CELG) conference call took place on July 23, 2015, 09:00 AM ET. This is a transcript of that earnings call:
CELG: 139.01 (+0.75)
Celgene Q2 Earnings & Revenues In Line, Keeps View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 12:26PM CDT
Celgene Corporation (CELG) reported second-quarter 2015 earnings of $1.08 per share (including stock-based compensation expenses and tax adjustments), in line with the Zacks Consensus Estimate.
RCPT: 228.27 (-0.13), JUNO: 51.65 (-0.12), AMAG: 71.31 (-1.23), CELG: 139.01 (+0.75)
Next Resistance Level for Celgene (CELG) is $141.45
Comtex SmarTrend(R) - Thu Jul 23, 10:18AM CDT
Shares of Celgene (NASDAQ:CELG) opened today above their pivot of $137.52 and have already reached the first level of resistance at $139.86. Investors may be interested in a cross of the next upside pivot targets of $141.45 and $145.38.
CELG: 139.01 (+0.75)
Uptrend Call Working As Celgene Stock Rises 18.8% (CELG)
Comtex SmarTrend(R) - Thu Jul 23, 10:05AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on June 19th, 2015 at $117.12. In approximately 1 month, Celgene has returned 18.80% as of today's recent price of $139.14.
CELG: 139.01 (+0.75)
Valeant Earnings Soar On M&A, Organic Sales Growth
at Investor's Business Daily - Thu Jul 23, 8:37AM CDT
Acquisition-hungry Valeant Pharmaceuticals (VRX) rose more than 5% in the stock market today to a record high, despite weak Q3 earnings guidance, after neatly stepping over analysts' second-quarter revenue and earnings expectations. Valeant was one...
ENDP: 85.90 (-0.62), VRX: 253.84 (+14.92), SHPG: 261.24 (+1.78), RCPT: 228.27 (-0.13), LLY: 86.76 (+0.38), BMY: 68.24 (-1.13), CELG: 139.01 (+0.75)
Celgene (CELG) Reports In Line Q2 Earnings and Revenues - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 8:25AM CDT
Celgene (CELG) Reports In Line Q2 Earnings and Revenues
CELG: 139.01 (+0.75)
Celgene beats Street 2Q forecasts
Automated Insights - Thu Jul 23, 7:06AM CDT
SUMMIT, N.J. (AP) _ Celgene Corp. (CELG) on Thursday reported second-quarter earnings of $356.2 million.
CELG: 139.01 (+0.75)
Celgene Reports Second Quarter 2015 Operating and Financial Results
Business Wire - Thu Jul 23, 6:30AM CDT
--POMALYST(R)/IMNOVID(R) Net Product Sales $235 Million; Increased 46% Y/Y
CELG: 139.01 (+0.75), CELGZ: 2.20 (-0.09)
Illumina Breaches Key Level On Q2 Sales Miss
at Investor's Business Daily - Wed Jul 22, 3:54PM CDT
Illumina (ILMN) surpassed second quarter earnings estimates late Tuesday but missed on revenue for the first time in six years. Analysts expected a beat-and-raise from the maker of gene sequencing systems, so its shares suffered in the stock market...
BIIB: 385.05 (-6.69), VRX: 253.84 (+14.92), DGX: 74.40 (+1.93), ILMN: 219.94 (+2.45), ABBV: 70.52 (-0.04), CELG: 139.01 (+0.75)
SmarTrend Watching for Potential Pullback in Shares of Celgene After 1.48% Gain
Comtex SmarTrend(R) - Wed Jul 22, 3:50PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $135.19 to a high of $139.12. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $137.99 on volume of 6.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 139.01 (+0.75)
Watch for Celgene to Potentially Pullback After Gaining 1.48% Yesterday
Comtex SmarTrend(R) - Wed Jul 22, 3:50PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $135.19 to a high of $139.12. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $137.99 on volume of 6.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 139.01 (+0.75)
Critical Alerts For Fitbit, MannKind, Celgene, Yahoo! and Zulily Released By InvestorsObserver
PR Newswire - Wed Jul 22, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FIT, MNKD, CELG, YHOO and ZU.
FIT: 46.20 (+0.67), YHOO: 39.21 (-0.03), MNKD: 5.42 (-0.04), ZU: 14.01 (+0.14), CELG: 139.01 (+0.75), CELGZ: 2.20 (-0.09)
5 Reasons Celgene Corporation Is a Buy
Brian Feroldi, The Motley Fool - Motley Fool - Wed Jul 22, 8:01AM CDT
Biopharmaceutical company Celgene is up more than 400% over the past five years, smashing the market's return and making a small fortune for long-term investors. Despite the huge run, there are plenty of reasons to be bullish on Celgene's stock....
RCPT: 228.27 (-0.13), JUNO: 51.65 (-0.12), CELG: 139.01 (+0.75)
Celgene Buys Receptos. Is Arena Pharmaceuticals Next?
Brian Orelli, The Motley Fool - Motley Fool - Tue Jul 21, 3:27PM CDT
Arena Pharmaceuticals (NASDAQ: ARNA) jumped more than 6% last Wednesday. But it had nothing to do with the biotech's only approved drug, obesity treatment Belviq. It wasn't even anything Arena Pharmaceuticals did. Instead, it appears the bump...
BIIB: 385.05 (-6.69), RCPT: 228.27 (-0.13), ARNA: 4.15 (-0.10), NVS: 103.05 (+1.75), CELG: 139.01 (+0.75)
What's in Store for Celgene (CELG) This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 21, 1:00PM CDT
Celgene Corporation (CELG) is scheduled to report second-quarter 2015 results on Jul 23, before the opening bell.
VRX: 253.84 (+14.92), ESRX: 93.06 (-1.02), MDCO: 34.00 (+0.16), CELG: 139.01 (+0.75)
Why This Analyst Expects New Alzhemier’s Trials Could Produce the Most Important Drugs in History
ESTMZ - Tue Jul 21, 11:24AM CDT
Welcome to the July 21st edition of This Week on Estimize. We are pleased to be joined by Joe McCann, former biotech analyst and founder of Slingshot Insights, a company that works to provide professional caliber investment tools to sophisticated...
BIIB: 385.05 (-6.69), SPY: 210.18 (-1.19), GILD: 117.66 (+0.22), ZGNX: 20.27 (-0.71), UTHR: 175.10 (+0.50), RTRX: 34.18 (-0.75), LLY: 86.76 (+0.38), CELG: 139.01 (+0.75), XOMA: 1.04 (+0.04)
3 Questions Investors Should Ask When Celgene Reports Its Second-Quarter Results
Sean Williams, The Motley Fool - Motley Fool - Tue Jul 21, 6:03AM CDT
Source: Food and Drug Administration via Facebook. Earnings season is heating up, which means that some of healthcare's biggest names are set to report their latest quarterly results. One of the first biotech blue-chip stocks up to bat in the...
CELG: 139.01 (+0.75)
Jim Cramer's Top Takeaways: Celgene, Facebook, Amazon.com, Netflix, Google
at The Street - Tue Jul 21, 5:00AM CDT
Cramer is delighted to see two of his favorite companies, Celgene and Receptos come together.
NFLX: 110.10 (-1.40), AMZN: 482.18 (-6.09), FB: 95.44 (-1.60), RCPT: 228.27 (-0.13), GOOGL: 674.73 (-20.37), CELG: 139.01 (+0.75)
Jim Cramer's 'Mad Money' Recap: Earnings Tsunami Heads Our Way
at The Street - Mon Jul 20, 7:31PM CDT
Cramer says you've got to listen to the commentary on earnings from Apple tomorrow, not to mention what's up with Microsoft and falling PC sales.
WWE: 17.23 (-0.38), DAL: 45.16 (-0.06), PYPL: 37.01 (-1.38), SBUX: 56.56 (-0.13), YHOO: 39.21 (-0.03), JNJ: 100.20 (+0.02), QCOM: 61.78 (-2.41), CMG: 725.94 (+0.12), HZNP: 38.08 (+0.17), RCPT: 228.27 (-0.13), AAL: 42.61 (+1.18), ABBV: 70.52 (-0.04), GOOGL: 674.73 (-20.37), CAT: 76.88 (-2.88), MSFT: 46.11 (+0.57), AAPL: 125.16 (-0.06), CSCO: 28.01 (+0.48), AMBA: 122.99 (+0.49), JOY: 27.86 (-0.48), KO: 40.84 (-0.06), AMZN: 482.18 (-6.09), ABT: 51.20 (+0.22), AXP: 77.01 (-1.98), FB: 95.44 (-1.60), LLY: 86.76 (+0.38), BA: 146.11 (-0.36), CELG: 139.01 (+0.75), NFLX: 110.10 (-1.40), UA: 95.93 (+6.56), NLY: 9.68 (-0.04), MCD: 97.09 (-0.49), VGR: 24.48 (-0.14), BABA: 83.88 (-0.27)
Celgene Rolling Along (but You Already Knew That)
Brian Orelli, The Motley Fool - Motley Fool - Thu Jul 23, 1:47PM CDT
The big picture numbers when Celgene released second quarter earnings Thursday weren't surprising since the company pre-released its revenue and earnings when it announced the acquisition of Receptos last week. But the details of where the...
RCPT: 228.27 (-0.13), ABBV: 70.52 (-0.04), CELG: 139.01 (+0.75)
Celgene (CELG) Earnings Report: Q2 2015 Conference Call Transcript
at The Street - Thu Jul 23, 1:11PM CDT
The following Celgene (CELG) conference call took place on July 23, 2015, 09:00 AM ET. This is a transcript of that earnings call:
CELG: 139.01 (+0.75)
Celgene Q2 Earnings & Revenues In Line, Keeps View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 12:26PM CDT
Celgene Corporation (CELG) reported second-quarter 2015 earnings of $1.08 per share (including stock-based compensation expenses and tax adjustments), in line with the Zacks Consensus Estimate.
RCPT: 228.27 (-0.13), JUNO: 51.65 (-0.12), AMAG: 71.31 (-1.23), CELG: 139.01 (+0.75)
Next Resistance Level for Celgene (CELG) is $141.45
Comtex SmarTrend(R) - Thu Jul 23, 10:18AM CDT
Shares of Celgene (NASDAQ:CELG) opened today above their pivot of $137.52 and have already reached the first level of resistance at $139.86. Investors may be interested in a cross of the next upside pivot targets of $141.45 and $145.38.
CELG: 139.01 (+0.75)
Uptrend Call Working As Celgene Stock Rises 18.8% (CELG)
Comtex SmarTrend(R) - Thu Jul 23, 10:05AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on June 19th, 2015 at $117.12. In approximately 1 month, Celgene has returned 18.80% as of today's recent price of $139.14.
CELG: 139.01 (+0.75)
Valeant Earnings Soar On M&A, Organic Sales Growth
at Investor's Business Daily - Thu Jul 23, 8:37AM CDT
Acquisition-hungry Valeant Pharmaceuticals (VRX) rose more than 5% in the stock market today to a record high, despite weak Q3 earnings guidance, after neatly stepping over analysts' second-quarter revenue and earnings expectations. Valeant was one...
ENDP: 85.90 (-0.62), VRX: 253.84 (+14.92), SHPG: 261.24 (+1.78), RCPT: 228.27 (-0.13), LLY: 86.76 (+0.38), BMY: 68.24 (-1.13), CELG: 139.01 (+0.75)
Celgene (CELG) Reports In Line Q2 Earnings and Revenues - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 8:25AM CDT
Celgene (CELG) Reports In Line Q2 Earnings and Revenues
CELG: 139.01 (+0.75)
Celgene beats Street 2Q forecasts
Automated Insights - Thu Jul 23, 7:06AM CDT
SUMMIT, N.J. (AP) _ Celgene Corp. (CELG) on Thursday reported second-quarter earnings of $356.2 million.
CELG: 139.01 (+0.75)
Celgene Reports Second Quarter 2015 Operating and Financial Results
Business Wire - Thu Jul 23, 6:30AM CDT
--POMALYST(R)/IMNOVID(R) Net Product Sales $235 Million; Increased 46% Y/Y
CELG: 139.01 (+0.75), CELGZ: 2.20 (-0.09)
Illumina Breaches Key Level On Q2 Sales Miss
at Investor's Business Daily - Wed Jul 22, 3:54PM CDT
Illumina (ILMN) surpassed second quarter earnings estimates late Tuesday but missed on revenue for the first time in six years. Analysts expected a beat-and-raise from the maker of gene sequencing systems, so its shares suffered in the stock market...
BIIB: 385.05 (-6.69), VRX: 253.84 (+14.92), DGX: 74.40 (+1.93), ILMN: 219.94 (+2.45), ABBV: 70.52 (-0.04), CELG: 139.01 (+0.75)
SmarTrend Watching for Potential Pullback in Shares of Celgene After 1.48% Gain
Comtex SmarTrend(R) - Wed Jul 22, 3:50PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $135.19 to a high of $139.12. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $137.99 on volume of 6.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 139.01 (+0.75)
Watch for Celgene to Potentially Pullback After Gaining 1.48% Yesterday
Comtex SmarTrend(R) - Wed Jul 22, 3:50PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $135.19 to a high of $139.12. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $137.99 on volume of 6.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 139.01 (+0.75)
Critical Alerts For Fitbit, MannKind, Celgene, Yahoo! and Zulily Released By InvestorsObserver
PR Newswire - Wed Jul 22, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FIT, MNKD, CELG, YHOO and ZU.
FIT: 46.20 (+0.67), YHOO: 39.21 (-0.03), MNKD: 5.42 (-0.04), ZU: 14.01 (+0.14), CELG: 139.01 (+0.75), CELGZ: 2.20 (-0.09)
5 Reasons Celgene Corporation Is a Buy
Brian Feroldi, The Motley Fool - Motley Fool - Wed Jul 22, 8:01AM CDT
Biopharmaceutical company Celgene is up more than 400% over the past five years, smashing the market's return and making a small fortune for long-term investors. Despite the huge run, there are plenty of reasons to be bullish on Celgene's stock....
RCPT: 228.27 (-0.13), JUNO: 51.65 (-0.12), CELG: 139.01 (+0.75)
Celgene Buys Receptos. Is Arena Pharmaceuticals Next?
Brian Orelli, The Motley Fool - Motley Fool - Tue Jul 21, 3:27PM CDT
Arena Pharmaceuticals (NASDAQ: ARNA) jumped more than 6% last Wednesday. But it had nothing to do with the biotech's only approved drug, obesity treatment Belviq. It wasn't even anything Arena Pharmaceuticals did. Instead, it appears the bump...
BIIB: 385.05 (-6.69), RCPT: 228.27 (-0.13), ARNA: 4.15 (-0.10), NVS: 103.05 (+1.75), CELG: 139.01 (+0.75)
What's in Store for Celgene (CELG) This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 21, 1:00PM CDT
Celgene Corporation (CELG) is scheduled to report second-quarter 2015 results on Jul 23, before the opening bell.
VRX: 253.84 (+14.92), ESRX: 93.06 (-1.02), MDCO: 34.00 (+0.16), CELG: 139.01 (+0.75)
Why This Analyst Expects New Alzhemier’s Trials Could Produce the Most Important Drugs in History
ESTMZ - Tue Jul 21, 11:24AM CDT
Welcome to the July 21st edition of This Week on Estimize. We are pleased to be joined by Joe McCann, former biotech analyst and founder of Slingshot Insights, a company that works to provide professional caliber investment tools to sophisticated...
BIIB: 385.05 (-6.69), SPY: 210.18 (-1.19), GILD: 117.66 (+0.22), ZGNX: 20.27 (-0.71), UTHR: 175.10 (+0.50), RTRX: 34.18 (-0.75), LLY: 86.76 (+0.38), CELG: 139.01 (+0.75), XOMA: 1.04 (+0.04)
3 Questions Investors Should Ask When Celgene Reports Its Second-Quarter Results
Sean Williams, The Motley Fool - Motley Fool - Tue Jul 21, 6:03AM CDT
Source: Food and Drug Administration via Facebook. Earnings season is heating up, which means that some of healthcare's biggest names are set to report their latest quarterly results. One of the first biotech blue-chip stocks up to bat in the...
CELG: 139.01 (+0.75)
Jim Cramer's Top Takeaways: Celgene, Facebook, Amazon.com, Netflix, Google
at The Street - Tue Jul 21, 5:00AM CDT
Cramer is delighted to see two of his favorite companies, Celgene and Receptos come together.
NFLX: 110.10 (-1.40), AMZN: 482.18 (-6.09), FB: 95.44 (-1.60), RCPT: 228.27 (-0.13), GOOGL: 674.73 (-20.37), CELG: 139.01 (+0.75)
Jim Cramer's 'Mad Money' Recap: Earnings Tsunami Heads Our Way
at The Street - Mon Jul 20, 7:31PM CDT
Cramer says you've got to listen to the commentary on earnings from Apple tomorrow, not to mention what's up with Microsoft and falling PC sales.
WWE: 17.23 (-0.38), DAL: 45.16 (-0.06), PYPL: 37.01 (-1.38), SBUX: 56.56 (-0.13), YHOO: 39.21 (-0.03), JNJ: 100.20 (+0.02), QCOM: 61.78 (-2.41), CMG: 725.94 (+0.12), HZNP: 38.08 (+0.17), RCPT: 228.27 (-0.13), AAL: 42.61 (+1.18), ABBV: 70.52 (-0.04), GOOGL: 674.73 (-20.37), CAT: 76.88 (-2.88), MSFT: 46.11 (+0.57), AAPL: 125.16 (-0.06), CSCO: 28.01 (+0.48), AMBA: 122.99 (+0.49), JOY: 27.86 (-0.48), KO: 40.84 (-0.06), AMZN: 482.18 (-6.09), ABT: 51.20 (+0.22), AXP: 77.01 (-1.98), FB: 95.44 (-1.60), LLY: 86.76 (+0.38), BA: 146.11 (-0.36), CELG: 139.01 (+0.75), NFLX: 110.10 (-1.40), UA: 95.93 (+6.56), NLY: 9.68 (-0.04), MCD: 97.09 (-0.49), VGR: 24.48 (-0.14), BABA: 83.88 (-0.27)
